Abylqis: Withdrawal of the marketing authorisation application

arachis hypogaea extract


DBV Technologies withdrew its application for a marketing authorisation of Abylqis for the treatment of peanut allergies.

The company withdrew the application on 17 December 2021.

  • List item

    Questions and answers on the withdrawal for the marketing authorisation of Abylqis (Arachis hypogaea extract) (PDF/113.77 KB)

    First published: 28/01/2022
    Last updated: 23/11/2022

  • Key facts

    Product number
    International non-proprietary name (INN) or common name
    • arachis hypogaea extract
    Active substance
    • arachis hypogaea extract
    Date of withdrawal
    Company making the application
    DBV Technologies
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating